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Alzheimer’s disease (AD) is a neurodegenerative disorder primarily affecting regions of the brain responsible for higher cognitive
functions. Immunization against-amyloid (A) in animal models of AD has been shown to be effective on themolecular level but also
on the behavioral level. Recently, we reported naturally occurring autoantibodies against A (NAbs–A) being reduced in Alzheimer’s
disease patients. Here, we further investigated their physiological role: in epitope mapping studies, NAbs–A recognized the mid-/C-
terminal endofA andpreferentially bound tooligomersbut failed tobind tomonomers/fibrils.NAbs–Awere able to interferewithA
peptide toxicity, but NAbs–A did not readily clear senile plaques although early fleecy-like plaques were reduced. Administration of
NAbs–A in transgenicmice improved theobject locationmemory significantly, almost reachingperformance levels ofwild-type control
mice. These findings suggest a novel physiological mechanism involving NAbs–A to dispose of proteins or peptides that are prone to
forming toxic aggregates.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder pri-
marily affecting regions of the brain responsible for higher cog-
nitive functions, such as learning andmemory. Plaque deposition
and neurofibrillary tangles are the histopathological hallmarks
of AD. -Amyloid (A) peptides become deposited in those
plaques, and hence their clearance has been discussed as a major
therapeutic goal.
Emerging experimental evidence detected the early acidic en-
dosomes as the principal generation site for A peptides (Kaether
et al., 2006; Rajendran et al., 2006), and dimers, trimers, and
multimeric aggregates have been shown recently in vitro and in
transgenic (Tg) mice models to be crucial toxic species (Cleary et
al., 2005; Klyubin et al., 2005; Lesne´ et al., 2006; Townsend et al.,
2006; Glabe, 2008; Shankar et al., 2008; Tomic et al., 2009). It was
further suggested that small A oligomers may form intracellularly
before being released into the extracellular medium, in which they
may interfere with synaptic activity or act as seeds to accelerate fibril
formation (Selkoe, 2004; Khandogin and Brooks, 2007). Thus, pre-
venting or reversing the formation of aggregated amyloid would
appear to be a promising strategy for AD treatment.
Several therapeutic approaches are currently under consider-
ation, including active/passive immunization against A as pio-
neered by Schenk et al. (1999). In transgenic amyloid precursor
protein (APP)-expressing mice, immunization against A pep-
tides has been shown to be effective on both molecular and be-
havioral levels. Active immunization in transgenic mice reduced
fibril formation, promoted clearance of A plaques, and also inter-
fered with tau phosphorylation (Schenk et al., 1999; Morgan et al.,
2000). Moreover, passive immunization was also effective with an-
tibodies that recognized the N-terminal and the mid-terminal do-
mains of A peptides (DeMattos et al., 2001). Based on these data,
several clinical trials have been started (Mangialasche et al., 2010). In
patients treated with antibodies directed against the N terminus of
A, a considerable decrease in plaque load has been reported, but
clearance of already formed plaques might not be sufficient to im-
prove cognitive function in AD patients (Holmes et al., 2008).
Recently, we and others identified naturally occurring auto-
antibodies against A (NAbs–A) being reduced in patients with
AD (Du et al., 2001; Weksler et al., 2002). Naturally occurring
autoantibodies make up to two-thirds of the human antibody
pool and are known to have many functions; however, the un-
derlying mechanisms are far from being completely understood
(Shoenfeld et al., 2007). NAbs–A have been characterized in
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different experimental settings to inhibit the propensity of A to
fibrillize, thereby blocking its toxicity and to affect the clearance
of A (Dodel et al., 2004; Taguchi et al., 2008; Bacher et al., 2009;
Relkin et al., 2009). However, how NAbs–A interact with A
and promote their clearance remains to be elucidated. Here, we
show for the first time that NAbs–A interfered with, and
preferentially bound to early oligomerization products of A
peptide. Moreover, in a mouse model of AD, plaque formation
was reduced after passive immunization with NAbs–A and
the subsequent clearance of A led to a rapid improvement of
mice behavior.
Based on the concept of NAbs–A, commercially available
human Ig preparations (IVIg) have been used in small pilot trials
for the treatment of patients with AD (Dodel et al., 2010), which
showed promising effects on cognition, thus leading to a phase III
trial in the United States (Relkin et al., 2009).
Materials andMethods
Isolation of NAbs–A. We used purified human intravenous IgG (Oc-
tagam 5%) for the isolation of NAbs–A, which was kindly provided by
Octapharma AG. Octagam 5% liquid is a solvent/detergent-treated, ster-
ile preparation of highly purified IgG derived from large pools of human
plasma (10,000–20,000 of donations). The product is prepared by using
cold Cohn–Oncley ethanol fractionation process, followed by ultrafiltra-
tion and chromatography and contains50 mg of protein per milliliter
(5%). Ninety-six percent of protein represents human normal IgG
(IgA 0.2 mg; IgM 0.1 mg). It contains no more than 3% aggregates
and fragments, respectively, and no more than 90% monomers and
dimers with an Fc portion maintained intact. IgG subclasses are fully
represented (IgG 1, 65%; IgG 2, 30%; IgG 3, 3%; IgG 4, 2%). For the
following isolation steps, this preparation was mixed with an equal vol-
ume of PBS and loaded directly onto an affinity column.
Because the A1-40 sequence contains internal lysine residues that
might lead to side reactions in immobilization procedures using amino
groups, a specific affinity column was prepared using a cysteine residue
attached to the A N terminus to ensure homogeneous orientation of
peptide molecules on the column support by immobilization through
cysteinyl-S-thioether linkage. The azlactone-activated support contains
an iodoacetyl group (Ultralink; Perbio) at the end of a hexadecyl-spacer
group, which reacts with the cysteinyl-sulfhydryl group to yield a stable
thioether linkage to reduce steric hindrance and provide maximum
binding capacity of the antibodies. For covalent attachment of the Cys–
A1-40, 3.7 mg of peptide was dissolved in 50 mM Tris and 5 mM
EDTA-Na coupling buffer, pH 8.5, to a final concentration of 0.37 mg/
ml. The solution was added to 1 ml of drained Ultralink-Iodoacetyl gel,
and the coupling reaction was performed for 1 h at room temperature
under gentle mixing, followed by 30 min reaction time without mixing.
An aliquot of 0.5 ml of the Cys–A1-40 coupled support was packed into
a column (2.5 ml; MoBiTec) allowing the solution to drain. The column
waswashedwith 3ml of coupling buffer, andnonspecific binding sites on
the gel were blocked two times for 45min with 1ml of 50mM L-cysteine-
HCl in coupling buffer. Subsequently, the column was washed with 5 ml
of 1 M NaCl, 5 ml of 0.l M Na-phosphate, and 0.15 M NaCl, pH 7.2, and
stored at 4°C. The gel support (0.5 ml) was transferred into a 15 ml
Falcon vial using 5 ml of PBS and mixed with 5 ml of IVIg. After gentle
shaking overnight at 4°C, this suspension was transferred to the column
using the effluent to completely rinse the matrix back into the column.
The column was washed eight times with 10 ml of PBS, followed by two
wash cycles with 10 ml of ultrapure water.
The bound antibodies were eluted from the column with 10 0.5 ml
of 0.1 M glycine buffer, pH 2.8. Each fraction was collected in a microre-
action tube containing 35 l of 1 M Tris-HCl, pH 9. The flow-through
(FT) of this isolation procedure, which contains IgG depleted of NAbs–
A, was also collected and was used as a control in the respective exper-
imental settings.
To maintain the integrity of the antibodies, a neutral pH was adjusted
immediately after elution by adding the appropriate amount of Tris-HCI
or glycine buffer. To regenerate the column for additional use, the col-
umnwas washed once with 10ml of 10mMNa-phosphate buffer, pH 6.8,
followed by two wash cycles with 10 ml of PBS containing 1 M NaCl and
finally two wash cycles with 10 ml of PBS.
Antibody concentrations in the elution fractions were determined by
the Micro BCA Protein Assay kit method (Pierce; Perbio). The stock
solution of 2 mg/ml bovine albumin supplied within the Micro BCATM
kit was used to prepare fresh standard dilutions within the range 40–0.5
g/ml. The antibodies were eluted between fractions 1 and 6, with the
highest concentrations in fractions 1 and 3. For quantification of each set
of 10 elutions, fresh albumin standard dilutions were prepared. Results
were read at 562 nm with an ELISA reader.
Cell culture and toxicity assay. SH-SY5Y human neuroblastoma cells
were grown in RPMI 1640medium supplemented with 10% FCS, 10mM
HEPES, 4 mM glutamine, penicillin (200 U/ml), and streptomycin (200
g/ml) at 37°C in a 5% CO2 atmosphere. Cells were plated and kept
overnight at a density of 30,000 cells per well in a 96-wellmicrotiter plate.
After removal of medium, cells were washed with PBS, and toxic A
oligomers (2 M final concentration) (Kayed et al., 2003) were added in
100 l of fresh medium with either 7.5 or 15 M NAbs–A or without
NAbs–A. Each data point was determined in hexaplicate. MTT toxicity
assay with SH-SY5Y cells was performed according to the protocol of the
manufacturer.
Preparation of A. The lyophilized synthetic A1-40 (PSL GmbH) was
resuspended in 100% 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP) at 1
mg/ml and incubated for 1 h at room temperature. After evaporation of
HFIP, the peptide was resuspended according to the species of interest.
For preparation of the monomer, the synthetic A1-40 peptide was sus-
pended in ultrapure or double-distilled water at 1 mg/ml just before the
experiment. A dimers were prepared using A1-40 peptide with
N-terminal cysteine (Cys–A1-40) in 1 PBS at 1 mg/ml concentration
and centrifuged for 30 min at 12,000 rpm. The protein content of the
supernatant was quantified using Nanodrop and sonicated for 15 min at
65°C. The dimerwas generated by incubation at 37°C for 3 hwith shaking
(900 rpm). The trimer was generated by a double mutation of A1-40
peptide and resuspended in sodium carbonate buffer (1 mg/ml), pH 9.6,
Figure 1. NAbs–Awere able to block the neurotoxic effect of oligomeric A1-40 in neuro-
blastoma SH-SY5Y cells. SH-SY5Y cells (30,000 cells per well) were incubated alone or in the
presence of oligomerized A1-40 (prepared as described inMaterial andMethods). The viability
of the cells was determined by theMTT assay. There was a concentration-dependent inhibition
of A-induced cell death in the presence of NAbs–A. At a concentration of 15M NAbs–A,
an almost complete inhibition of A-induced cell death was observed. Using the FT in a con-
centration up to 15M did not block A-induced cytotoxicity. Values are expressed as percent-
age of control cultures for each experiment, and the data represent themean SE of triplicate
determinations from a representative experiment repeated at least three times with similar
results.
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after the HFIP treatment, which instantly formed the SDS-stable trimer.
Low-binding minicentrifuge tubes were used (Eppendorf) throughout
the experiments.
Characterization of A epitopes recognized by NAbs–A. Ninety-six-
well plates were coated with A1-40 and other peptides as outlined in the
respective figure [5g/ml; freshly resuspended in coating buffer (1.7mM
NaH2PO4, 98 mM Na2HPO4, pH 7.4, and 0.05% sodium azide)], and
incubated at 37°C for 2 h. The plates were then incubated with blocking
buffer (Pierce) at 37°C for 2 h.
HRP-labeled heavy and light chain-specific goat anti-human antibod-
ies were used as detection antibodies at 1:3000 dilution and incubated for
1 h at 37°C (Calbiochem). The reaction with a chromogenic substrate,
3,3,5,5-tetramethylbenzidine (Calbiochem), was terminated with 2N
H2SO4, and plates were read at 450 nm using a plate reader (Thermo
Fisher Scientific).
Size exclusion chromatography. A Superdex 75 10/30 HR column at-
tached to an AKTA FPLC system (GEHealthcare) was used for all exper-
iments and calibrated using unbranched dextran standards of the
following molecular masses: 123,600; 66,700; 43,800; 21,400; 9890; and
4440 Da (Pharmacosmos). -Amyloid (1 mg/ml) was injected onto the
Superdex 75 column and eluted with 50mM ammonium acetate, pH 8.5,
at a flow rate of 1 ml/min. One milliliter fractions were lyophilized,
resuspended in 2 SDS-tricine sample buffer (20 l), boiled for 10 min,
and then subjected to electrophoresis on 10–20% tricine gels. Proteins
were transferred onto 0.2 m nitrocellulose membranes and used for
Western blotting.
Surface plasmon resonance experiments. Immobilization of antibodies
and antibody/A interaction analyses were performed on a Biacore 2000
optical biosensor system. Each antibodywas immobilized via amino cou-
pling (Biacore) up to 8500–10,000 response units on CM5 sensor chips
(Biacore). Then, 60 l of analyte (A oligomers) was injected on sensor
chips surfaces at a flow rate of 15 l/min and in various concentrations
(0.1–100 g/ml). PBS and a carbonate-bicarbonate buffer were used as
running buffers as specified. A samples were kept at 4°C before each
injection over the sensor chip at 25°C. Surface plasmon resonance (SPR)
chip regeneration was performed using 6.25–50 mM NaOH. Binding
analysis was performed using BIA evaluation 3.2RC1 software (Biacore).
Animals and drug treatment. We investigated female CRND8 trans-
genic mice carrying a double-mutated form of the human amyloid pre-
cursor protein 695 (APP695; the Swedish and Indiana mutations) under
the control of the Syrian hamster prion promoter, on a hybrid C57BL/
6–C3H/ HeJ background (courtesy of D. Westaway, University of To-
ronto, Toronto, Canada) (Chishti et al., 2001). Compared with other
murine models of AD (Ro¨skam et al., 2010), TgCRND8mice exhibit A
plaques at a very young age (at 3 months), accompanied by cognitive
deficits (Lovasic et al., 2005; Bacher et al., 2008). At 3 months (“young”;
n  15) or 12 months (“old”; n  15) of age, mice were injected intra-
peritoneally once a week for the duration of 4 weeks with either a low (80
g) or high (200g) dose of NAbs–A or with 200M FT (n 5). In all
experiments, the column FT was used as negative control (see above). In
addition, female APP23 transgenic mice, which express the human
APP751 isoform with the Swedish double mutation (K670N–M671L)
under control of a murine Thy1.2 expression cassette (courtesy of Dr.
Matthias Staufenbiel, Novartis Institutes for Biomedical Research, Basel,
Switzerland) were used. The animals were hemizygous or littermate con-
trols and had been backcrossed with C57BL/6J mice for at least eight
generations (Sturchler-Pierrat et al., 1997). Mice were housed in groups
of three to four animals in standard cages (37 cm length 21 cmwidth
15 cm height) together with wild-type littermates with food and water
Figure 2. Effect of NAbs–A on plaque deposition and plaque load in transgenic APP TgCRND8mice.A–D, Effect of NAbs–A on plaque number (C) and plaque area (D) in old (age, 13months)
transgenic APP TgCRND8mice. Transgenicmicewere injected intraperitoneally once aweek for the duration of 4weekswith either FT after NAbs–Apurification as control (control, 200g;A;n
10) orwith a low (80g; C,D; n 7) and high (200g;B–D; n 8) dose of NAbs–A, respectively. E–H, Effect of NAbs–A on plaque number (G) and plaque area (H ) in young transgenicmice
(age, 4months). Transgenicmicewere injected intraperitoneally once aweek for the duration of 4weekswith either FT (flow-through depleted of NAbs–A; 200g; control; E; n 7) or a low (80
g;G,H; n 7) and high (200g; F–H; n 8) dose of NAbs–A, respectively. In old TgCRND8mice, NAbs–A did not affect the plaque loadwhen comparedwith vehicle (FHT)-treated animals
(B–D), whereas in youngmice plaque number and plaque area was significantly suppressed after 4 weeks of treatment (F–H ). The plaque density was significantly reduced after 4 weeks of both
high (by 24%) and low (by 34%) dose treatmentwith NAbs–A (p 0.045 and 0.026, respectively; the difference between the low and the high dose in the respective figureswas not significant).
Furthermore, a reduction of plaque area by 47%was detected after high (p 0.029) and low (p 0.028) dose applications of NAbs–A (H ). Animalswere killed 5 d after the last injection. Sagittal
sections from FT- and NAbs–A-treated young and old mice were stained for A using anti-human A monoclonal antibody 6F/3D. The average number (C, G) and area (D, H ) of A-
immunoreactive deposits were quantified semiautomatically in the cortex and hippocampus (12 sections per brain were analyzed). Results were analyzed using a two-tailed Student’s t test. Error
bars represent the SD. I, J, Concentration of A in CSF and plasma of APP transgenic mice after treatment with NAbs–A. The concentration of A in CSF (I ) and plasma (J ) was determined after
the last treatment with NAbs–A. There was an increase of the A concentration in the plasma and a decrease of the A concentration in CSF.
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available ad libitum. All experimental procedures were in accordance
with the guidelines of the local animal care commission.
Brain tissue preparation.Mice were decapitated 5 d after the last injec-
tion. Brains were removed, and one hemisphere was immediately snap-
frozen in liquid nitrogen and kept at 80°C until use. The other
hemisphere was fixed in 4% buffered formaldehyde for 24 h, followed by
dehydration and paraffin embedding.
Immunohistochemistry. ForA staining, six pairs of 2msagittal brain
sections of each transgenic animal were pretreated with formic acid and
incubated in a TechMate instrument (Dako) with 6F/3D (anti-A
monoclonal antibody directed against residues 8–17; 1:100; Dako). The
second step used the Dako StreptABC complex horseradish peroxidase-
conjugated anti-mouse/rabbit antibody kit, and staining was developed
with 3,3-diaminobenzidine. Counterstaining was performedwith hema-
toxylin. The pairs of sections (10 m distances) were situated 100, 200,
300, 400, 500, and 600m laterally from themidsagittal fissure. All slides
were stained in five consecutive procedures, ensuring that the brains of
all three experimental groups were equally distributed.
Morphometry of the A plaques. To quantify the A plaque burden,
neocortices and hippocampi of all stained sections were digitized (Olym-
pus BX50, ColorView II, charge-coupled device camera; Olympus) un-
der constant light and filter settings. Color images were converted to
grayscale by extracting blue to gray values to obtain the best contrast
between positive immunoreactivity and the background. A constant
threshold was chosen for all images to detect immunoreactive staining
(analySIS 5; Soft Imaging System). The total number and size of plaques
were determined. Absolute values of plaque burden were related to the
investigated area.
Behavioral experiments. Fourteen- to 16-month-old Tg2576 mice ex-
pressing the Swedish mutation (K670N/M671L) of APP695 under the
control of the hamster prion promoter, on a hybrid C57BL/6–SJL back-
ground (Hsiao et al., 1996), were intraperitoneally injected with either
400g of NAbs–A dissolved in 200l of PBS (n 21) or 200l of PBS
only (n 20). An additional group of age-matched wild-type mice were
treated with PBS (n 20).
To investigate the treatment efficacy of NAbs–A on spatial memory,
we performed the object location test (Hale and Good, 2005). In brief,
animals are introduced to two identical objects in an experimental appa-
ratus and, after a delay, are exposed again to the same two objects, one of
which has been displaced to a new location. Animals that remember the
previous exposure spontaneously spend more time exploring the object
in the new position. On the day of testing, mice were submitted to two 10
min trials with a 30 min intertrial delay. In trial 1, mice were allowed to
explore two similar objects located on one side of the cage for 10 min. In
trial 2, one of these objects was moved to a different location, and the
mice were allowed to explore the object for another 10 min. For analysis,
a discrimination ratio (DR) (time spent on the object in the new location
versus the total time spent exploring both objects in the test trial) was
calculated for each mouse. Object location test was reflected by more
time spent interacting with the object in the new location than with the
object in the familiar position and a DR above 0.5. Analysis of DRs is less
subject to the influence of individual variability in contact times with
objects and provides a measure of the extent of the discrimination be-
tween the novel and sample objects.
Murine anti-human antibody response. To investigate the murine anti-
human antibody (MAHA) response, we treated 10 wild-type mice (C57
BL/6 genetic background of TgCRND8 mice used in drug treatment
experiments) with 200 g of NAbs–A once a week for a period of 28 d
(Imboden et al., 2001). Blood was taken before and after the treatment
and investigated by MAHA ELISA. Briefly, plates were coated overnight
at 4°C with 5 g/ml human IgG1, diluted in sodium bicarbonate buffer,
pH 9.6. After washing four times with 1 PBS, 0.05% Tween 20, pH 7.4,
plates were blocked for 3 h with SuperBlock (Thermo Fisher Scientific).
After washing four times with 1 PBS, 0.05% Tween 20, pH 7.4, the
serum samples were diluted 1:100 and added to the wells for overnight
incubation at 4°C. The wells were then washed four times with 1 PBS
and 0.05% Tween 20, pH 7.4, and then 0.1 g/ml HRP-conjugated goat
anti-mouse IgG was added and plates were incubated for 1 h at room
temperature. Plates were thenwashed four timeswith 1PBS and 0.05%
Tween 20, pH 7.4. A total of 100 l of tetramethylbenzidine (Calbio-
chem) substrate was added to each well. The plates were incubated for 10
min, and then the reaction was stopped by the addition of 25 l/well of
2NH2SO4. The plates were read at 450 nmwith a 570 nm reference filter.
The standard curve reagent used for this assay was obtained by perform-
ing these measurements on serial dilutions of mouse anti-human IgG1
(BD Biosciences Pharmingen) in concentrations between 1 and 1000
ng/ml in twofold increments.
Statistical analysis. Data were analyzed using the Student’s t test or
ANOVA as appropriate. All tests were applied (two tailed) using the
software package SPSS (version 12.0.1). Differences were considered sig-
nificant at p 0.05.
Results
To assess whether purifiedNAbs–Awere protective against A-
induced cell death, we used A preparations consisting of oli-
gomerized products (Kayed et al., 2003). NAbs–A were able to
block the toxic effects of A oligomers in SH-SY5Y cells in a
concentration-dependent manner (Fig. 1). Cell death was re-
duced by 80% in the presence of NAbs–A. Ig preparations
lacking NAbs–A (flow-through of IVIg after isolation of NAbs–
A) administered at concentrations up to 15Mwere not able to
block the cytotoxic effects in this assay (Fig. 1).
Therapeutic efficacy of immunization has been associated
with the clearance of plaques in the brain of transgenic mice
(Schenk et al., 1999). Therefore, we investigated the ability of
NAbs–A to resolve plaque burden in APPTgCRND8 transgenic
mice (Chishti et al., 2001). We examined the effect of a low (80
g) and high (200 g) dose of purified NAbs–A on A plaque
deposition by immunohistochemical staining and image analysis
Figure 3. Immunohistochemistry to investigate the binding properties of theN-terminalmono-
clonalantibodiesandNAbs–A toamyloiddeposits intransgenicAPP23miceandinbrainsamplesof
ADandhumancerebralamyloidangiopathy.APP23micewereusedinthissetofexperimentsbecause
of their higher depositionofA in vasculature. Similar resultsweredetectedwith respect to amyloid
deposition inTgCRND8mice.A, ImmunostainingofabrainsamplefromanAPP23mousewithNAbs–
A: no specific stainingof theplaque (P) in the cortex is detectable. The inset represents the identical
area with a positive staining using the 6F/3D monoclonal antibody. B, Immunostaining of a brain
sample from an APP23mousewith NAbs–A: no specific staining of amyloid deposits in the vessel
(V	) is detectable (the inset represents the identical area with positive staining using the 6F/3D
monoclonal antibody). C, Immunostaining of a brain sample fromanAD patientwith NAbs–A: no
specific staining of a plaque (P) is detectable. The inset represents the identical area with positive
staining using the 6F3Dmonoclonal antibody.D, Immunostaining of a brain sample from a cerebral
amyloid angiopathy patient with NAbs–A: no specific staining of amyloid deposits in the small
vessels (V	) is visible, but there are some unspecific chromogen reactionswith the Nissl substance.
The inset represents the identical areawith positive staining using the 6F3Dmonoclonal antibody.
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in young (4 months) and old (13 months) TgCRND8 mice. To
avoid the MAHA response, treatment with the foreign antibody
was limited to 4 weeks to prevent an adverse MAHA immune
response in the animal model. To investigate the MAHA re-
sponse, we injected 10micewith 200g ofNAbs–A once aweek
for 28 d. As expected, all animals developed Ig against human IgG
(baseline, 0.001mg/ml; at 28 d, 0.017mg/ml).However, the titers
were lowwithin the group of 10 animals, seven animals had a titer
of 0.01 mg/ml, and only one animal (0.06 mg/ml) had a titer
above 0.05 mg/ml. None of the animals died or exhibited clinical
or behavioral changes. None of the inspected organs showed
changes as investigated by pathological and histopathological
examinations.
The cerebral plaque load in senescent
animals remained unaffected after 4
weeks of treatment with either low or high
doses of NAbs–A when compared with
age-matched sham-treated animals (Fig.
2A–D). In contrast, both low- and high
dose-treated young transgenic mice had a
significant reduction of plaque number
(high dose, by 24%, p  0.045; low dose,
by 34%, p 0.026) and plaque area (high
dose, by 47%, p  0.029; low dose, by
47%, p 0.028) (Fig. 2E–H). The differ-
ences between the high and the low doses
in young animals were not significant.
A disturbance in the equilibriumof the
central and the peripheral pool of A was
assumed to take place after immunization
against A; a phenomenon termed “pe-
ripheral sink hypothesis” (Dodart et al.,
2002; Dodel et al., 2002). Because the
NAbs–A had no plaque-dissolving ben-
efit in the old animals, we further investi-
gated their effect on the concentration of
A in CSF and plasma of immunized an-
imals. We detected a significant reduction
of CSF A in the animal group treated
with NAbs–A (Fig. 2). In plasma, an in-
crease of A was detectable, indicating an
efflux of A from the central pool into the
periphery (Fig. 2 J). In contrast, CSF and
plasma levels of A did not change con-
siderably when treated with FT for the
same period.
Interestingly, NAbs–A failed to de-
tect plaques in brain samples of transgenic
APP-expressing mice (Fig. 3A,B), AD pa-
tients (Fig. 3C), and patients with cerebral
amyloid angiopathy (Fig. 3D). In contrast,
antibodies such as 6F/3Ddetected plaques
in both animal and human brain samples.
Similar results were found when
NAbs–A was used to detect A in the
brain vasculature of patients with cere-
bral amyloid angiopathy (Fig. 3D).
Antibodies raised against the A
epitopes 4–10 have been reported to bind
to plaques in the brains of transgenic ani-
mals (McLaurin et al., 2002). Therefore,
we determined the linear sequences and
the conformational epitopes that were
recognized by NAbs–A using a large set of synthetic peptides
derived from the A sequence (Fig. 4A). TheNAbs–A bound to
the full-length A but not to the albumin control. The epitope re-
gion recognized byNAbs–A encompassed the residues 28–40(42)
of the A sequence (Fig. 4A), whereas N-terminal fragments were
not recognized by NAbs–A. The peptides with an altered amino
acid as well as the scrambled peptide did not show a binding signal.
The relevant amino acids within the epitope were confirmed by an
alanine scan of the C-terminal region of A.
Using size exclusion chromatography to separatemonomeric,
dimeric, and trimeric forms of A as described previously (Walsh
et al., 2005), we found that NAbs–A preferentially recognized
dimers and trimers and, to a lesser extent, monomeric forms of
Figure 4. A, Mapping of the A epitope recognized by NAbs–A using ELISA. Various peptides representing different parts of
the A sequencewere tested for the avidity of NAbs–A to bind in ELISA. The binding experiments showed an increased binding
of the NAbs–A toward the C-terminal region. We identified sequence AA28–40(42) as the major binding site. N-terminal
regions of the A peptide showed only low binding with the A reversed sequence (A40-1). The following peptides (with and
without exchanged amino acids) were also investigated: A1-40; A1-42; A1-12; A1-15; A10-28; A20-38; A20-31; A25-40;
A26-42; A28-42; A30-42; A1-40;G25A; A1-40;S26A; A1-40;G29I;G33I; A1-42;G29I;G33I; A1-40;D23K;K28D; A1-40;G29I;G33I;A42I; A1-
40;M35A;V40A; A1-40;I32A;M35A; A1-40;I32A;V40A; A1-40;I32A; A28-42;A30G; A28-42;G33A; A28-42;M35A; A28-42;V39C; A28-42;I32A;
A28-42;I32A;M35A;V40A. B, Dot blots of various peptide samples of SEC fractions of A were applied on nitrocellulose membrane
(0.25g/3l spot). The mid-terminal antibody (MTA) directed against residues AA16–24 readily recognized monomeric and
oligomeric forms of A, whereas NAbs–A only interacted with dimeric and trimeric forms but not monomeric forms. C–E,
Immobilizationand interactionanalyses ofmonoclonal antibodies andNAbs–A toA1-40 and its different oligomeric formswere
performed on a Biacore 2000 optical biosensor system. C, NAbs–A preferentially bound to dimers, and also to trimers, but not to
the monomeric form of A. D, The on-rate of the monoclonal antibody MTA to A was higher compared with the on-rate of
NAbs–A. E, Therewas a dose-dependent on-rate of the binding of NAbs–A to A1–40. OD, Optical density; RU, response units.
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A (Fig. 4B). In contrast, amonoclonal antibody recognizing the
mid-terminal part of the A sequence detected all three investi-
gated A oligomers. The affinity of NAbs–A to the different A
assemblies using SPR are shown in Figure 4C–E.
Furthermore, in behavioral experiments in the Tg2576 trans-
genic mice, the object location memory improved significantly
after the administration of NAbs–A and almost reached perfor-
mance levels of wild-type control mice. Mice treated with PBS
regularly performed at chance levels (discrimination ratio: 0.5
50%),whereasNAbs–A-treated animals and age-matchedwild-
typemice performed above chance ( p 0.001, ANOVA) (Fig. 5).
Discussion
To the best of our knowledge, this is the first report to link natu-
rally occurring autoantibodies to a physiological effect in theme-
tabolism of peptides that are toxic to humans. We found that
NAbs–A were readily detectable in healthy individuals, inter-
acted with A, and promoted its degradation. In epitope map-
ping, NAbs–A detected the mid-/C-terminal epitope of A,
starting at the amino acid AA28. Interestingly, they were not able
to bind and clear plaques, but they were
able to improve behavioral changes in a
transgenic mice model. Therefore, the
question is, how may NAbs–A work if
they can only recognize the mid-/C-end-
terminal part of A? According to recent
solid-nuclear magnetic resonance spectros-
copy studies of A oligomerization, the A
residues 12–24 and 30–40 adopt -strand
conformations and form parallel [or anti-
parallel, according to a proposed model
(Petkova et al., 2005)] -sheets through in-
termolecular hydrogenbonding (Petkova et
al., 2002). This process is followed by oli-
gomerization of the A peptides, as shown
inFigure 6.After fibrillation, theC-terminal
part of the A peptide is masked. However,
if anantibody is intendedtoblockoligomer-
ization, the C-terminal part of the A pep-
tide must be recognized for the antibody to
bind to it. If an antibody recognizes the
N-terminal part of the A peptide, oli-
gomerization and fibrillation of the peptide
may still continue. Therefore, to block these
processes that result inplaque formation, an
antibody appears to be useful that interferes
with the C-terminal part of the A peptide.
In the active immunization studies,
fibrillated A peptide was used as antigen.
It is likely that N-terminal epitopes of the
A peptide were predominantly exposed
and were available as binding sites. Ac-
cordingly, active immunization generated
primarily antibodies that recognized the
N-terminal epitope (AA4–10) of the A
sequence (McLaurin et al., 2002). Fur-
thermore, A peptide is deposited in a
fibrillar form in the plaques, and the
N-terminal part of the A peptide is predominantly available at
the “outside” of the plaque as an “epitope” for N-terminal active
antibodies.
In contrast, NAbs–A—as mainly directed to the mid-/C-
terminal epitope of A—were in fact not capable of binding to
the N terminus of A. This finding could also explain why our
NAbs–A did not clear plaques.
Furthermore, we found that our NAbs–A preferentially
bound to dimers and trimers and interferedwith oligomerization
(Britschgi et al., 2009). This may be the mechanisms why treat-
Figure 5. Neuropsychological testing in Tg2576 mice. Mean discrimination ratios for
14- to 16-month-old Tg2576 mice treated with either NAbs–A or PBS. NAbs–A-
immunized Tg2576 mice but not PBS-treated Tg2576 mice showed a preference for ex-
ploring objects moved to a new location, indicated by a discrimination ratio above 0.5
(NAbs–A group, n 21; PBS group, n 20; wild-type group, n 20; ***p 0.001).
Error bars show SEM. WT, Wild type.
Figure 6. A, Currently known epitopes of the A sequence. The NAbs–A recognized a distinct C-terminal epitope compared
with antibodies generated against the N terminus by active immunization in transgenic mice and promoted clearance of amyloid
plaques (McLaurin et al., 2002). The T-cell activation sites and the B-cell epitope have been identified at AA14–34 and AA4–10,
respectively (Monsonego et al., 2001). B, Assembly of A as proposed by Petkova et al. (2002, 2005). Central A1--40 molecules
from the energy-minimized, five-chain system, viewed down the long axis of the fibril. Residues are color coded according to their
side chains as hydrophobic (green), polar (magenta), positive (blue), or negative (red). C, Possible mode of lateral association for
generating fibrils with greater mass-per-length and greater cross-sectional dimensions. Assembly of oligomers started at mid-
terminal and C-terminal parts of the A peptide. Therefore, active immunization with A led to the generation of N-terminal
antibodies because only the N-terminal part was available for T-cell interaction. Accordingly, only N-terminal antibodies were
effective in removingplaquesbecauseonlyN-terminal partswere easily accessible to antibodies. In contrast, NAbs–A recognized
the dimeric form of A and interfered with further assembly of monomers to oligomers. B and C are reproduced with permission
from Proceedings of the National Academy of Sciences of the United States of America.
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ment with NAbs–A in young animals led to a reduction in
plaque number and size, suggesting that they acted by preventing
plaque formation.
Interestingly, NAbs–A failed to interact with other
aggregating/-sheet promoting proteins, such as -synuclein
and prion proteins (data not shown) (Du et al., 2003). Because
naturally occurring antibodies do not bind to distinct protein
sequences but rather recognize specific patterns of conservative
molecules, we hypothesized thatNAbs–Amay recognize a com-
mon conformational epitope among those proteins; our current
data, however, suggest that NAbs–A display a rather narrow
epitopal recognition pattern.
Recently, Shankar et al. (2008) pinpointed small assemblies of
A as “disease causation of AD” (Shankar et al., 2008). This in-
teractionwith small oligomers is pivotal ifNAbs–Aplay a role in
the metabolism of A peptides. However, targeting dissolved
plaques is not the primary goal because these plaques are inert
reservoirs (“garbage dump”) and they help to trap toxic oligom-
ers in the brain. Recent evidence from preclinical experimental
studies as well as data from clinical trials support this notion
(Holmes et al., 2008).
Although our data showed an efflux of central A into the
periphery that favored the efflux hypothesis of A clearance (pe-
ripheral sink) (DeMattos et al., 2002), it was noticeable that a
small amount of NAbs–A was capable of crossing the blood–
brain barrier and penetrating into the brain, as was shown using
radiolabeled NAbs–A (Bacher et al., 2009). In previous studies,
this small amount of autoantibodies available in the brain was
suggested to be sufficient to induce uptake by opsonization in the
brain (Schenk et al., 1999; Bard et al., 2000; Hock et al., 2002).
Therefore, we cannot rule out that additional mechanisms, in-
cluding a central degradation of A oligomers in the presence of
NAbs–A by microglial cells, may occur in the brain.
In summary, we suggest that NAbs–A, as part of the autoan-
tibody pool, have a physiological role and convey a protective
effect by inhibiting oligomerization of A peptides and conse-
quently degrading A. We further postulate that this protective
effect is primarily mediated through interactions with the mid-/
C-terminal parts of theA peptide andmay involve oligomerized
products of A. Furthermore, the increase of NAbs–A in the
serum probably disrupts the equilibrium between central and
peripheral A pools, leading to a shift from the CNS to the
periphery.
Finally, supportive evidence for the pivotal role thatNAbs–A
may play in the protection from AD comes from clinical studies
using IVIg preparations that containNAbs–A. IVIg has shown a
potentially positive effect on behavioral symptoms inADpatients
(Dodel et al., 2004; Relkin et al., 2009). We are fully aware that
these pilot studies only included a small number of patients. Nev-
ertheless, these preliminary clinical results, along with our exper-
imental results reported here, warrant a large clinical trial to
investigate the effects of IVIg and human NAbs–A in patients
with AD. A respective phase-III trial is currently underway in the
United States of America and results will be most likely available
by 2013.
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